R&D From genetic insight to Phase 3: What rare neurology require... Rare neurology is not defined by a lack of scientific opportunity or capital.
Sales & Marketing A fast start to 2026 signals continued investor confidence i... Key factors in Switzerland’s success that could make other European life sciences hubs more attractive to investors.
Market Access Capital efficient trials in a time of economic uncertainty In the current climate of capital constraints, tariffs, and policy uncertainty, as well as changing regulatory dynamics, pharma and biotech companies should address not just whether a trial
Patients Every drug is a story, with Thomas Goetz Thomas Goetz, creator and host of the Drug Story podcast on recognising pharmaceutical medicine as the socially and morally complex market that it is.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
